DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Xarelto (Rivaroxaban) - Published Studies

 
 



Xarelto Related Published Studies

Well-designed clinical trials related to Xarelto (Rivaroxaban)

Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. [2014]

Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). [2014]

Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. [2014]

Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF trial. [2014]

Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF. [2014]

Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trial. [2013]

Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study). [2011]

Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. [2011]

Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. [2010]

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. [2009]

A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. [2008]

Randomized, Double-Blind, Crossover Study to Investigate the Effect of Rivaroxaban on QT-Interval Prolongation. [2008]

Well-designed clinical trials possibly related to Xarelto (Rivaroxaban)

Aspirin for prevention and treatment of venous thromboembolism. [2014]

New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. [2013]

The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51). [2013]

Anticoagulating obese patients in the modern era. [2011]

Other research related to Xarelto (Rivaroxaban)

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). [2015]

Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. [2014]

Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. [2014]

Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. [2014]

Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials. [2013]

Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective. [2013]

Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. [2013]

Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber. [2013]

Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51). [2013]

Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. [2013]

Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. [2013]

Rivaroxaban for the treatment of acute coronary syndromes. [2013]

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. [2012]

Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes. [2012]

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. [2012]

The use of rivaroxaban for short- and long-term treatment of venous thromboembolism. [2012]

[Effect of rivaroxaban on risk of bleeding after total knee arthroplasty]. [Article in Chinese] [2011]

Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. [2011]

Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update. [2011]

A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement. [2011]

Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. [2010]

Other possibly related research studies

Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. [2012]

Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation. [2012]

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. [2012]

Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation. [2012]

Novel anticoagulants for non-valvular atrial fibrillation. [2012]

Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. [2012]

Newer anticoagulants in cardiovascular disease: a systematic review of the literature. [2012]

The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War? [2012]

Antiplatelet agents and anticoagulants for hypertension. [2011]

Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial. [2011]

New options for stroke prevention in atrial fibrillation. [2010]

New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors. [2010]

The new oral anticoagulants, do they change the benefit vs. risk for thromboprophylaxis in association to ambulatory surgery? [2010]

Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials. [2014]

Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients. [2014]

New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics? [2014]

Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. [2014]

Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. [2014]

Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy. [2014]

Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. [2014]

New oral anticoagulants and the cancer patient. [2014]

New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons. [2013]

Benefit-to-harm ratio of thromboprophylaxis for patients undergoing major orthopaedic surgery. A systematic review. [2014]

Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. [2014]

Is there a need for "triple therapy"? Role of anticoagulation with dual antiplatelet therapy in acute coronary syndromes (ATLAS Study & TRAP Study). [2013]

Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation. [2013]

New oral anticoagulants in elderly patients. [2013]

Bleeding and antidotes in new oral anticoagulants. [2013]

NOACs for thromboprophylaxis in medical patients. [2013]

Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery. [2013]

New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism. [2013]

New oral anticoagulants for the treatment of venous thromboembolism. [2013]

Novel oral anticoagulants in secondary prevention of stroke. [2013]

Disadvantages of VKA and requirements for novel anticoagulants. [2013]

Do women bleed more than men when prescribed novel oral anticoagulants for venous thromboembolism? A sex-based meta-analysis. [2013]

Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. [2013]

Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. [2013]

Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomized controlled trials. [2013]

Stroke prevention in atrial fibrillation patients with chronic kidney disease. [2013]

Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease. [2013]

Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. [2013]

Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach. [2013]

[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?]. [Article in German] [2013]

The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematic review and meta-analysis. [2013]

Use of new oral anticoagulants in antiphospholipid syndrome. [2013]

Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care. [2013]

Target-specific oral anticoagulants in atrial fibrillation: results of phase III trials and comments on sub-analyses. [2013]

Safety of new oral anticoagulants with dual antiplatelet therapy in patients with acute coronary syndromes. [2013]

Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke. [2014]

New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics? [2014]

Aspirin combined with mechanical measures to prevent venous thromboembolism after total knee arthroplasty: a randomized controlled trial. [2014]

Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm. [2014]

Beyond warfarin: a patient-centered approach to selecting novel oral anticoagulants for stroke prevention in atrial fibrillation. [2014]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017